Curewell Capital Invests in Wilmington PharmaTech to Boost Growth

Wilmington PharmaTech (WPT), a manufacturer of small molecule active pharmaceutical ingredients (APIs), has secured a majority investment from the private equity firm Curewell Capital, based in Los Angeles. The transaction aims to enhance WPT’s growth trajectory and fortify its domestic manufacturing capabilities in the pharmaceutical sector.

Founded in 2003, Wilmington PharmaTech has established itself as a key player in the pharmaceutical industry, providing integrated services that cover discovery, clinical development, and commercial-scale manufacturing. The company operates from its 54-acre campus in Delaware, featuring two modern facilities equipped with current Good Manufacturing Practice (cGMP) and high potency API suites, alongside a research and development center located in Suzhou, China.

Investment to Facilitate Expansion

Dr. Hui-Yin “Harry” Li, the founder and CEO of Wilmington PharmaTech, will maintain a significant ownership stake and continue to lead the company in collaboration with its existing management team. “Together with Curewell Capital, we look forward to accelerating our growth strategy by leveraging our core competencies,” Dr. Li stated. He emphasized the company’s commitment to enhancing its capabilities and capacity to better serve its global biopharmaceutical partners.

The partnership is expected to provide substantial growth capital aimed at expanding WPT’s manufacturing footprint. Michael Dal Bello, a partner at Curewell Capital, acknowledged the increasing demand for specialized pharmaceutical manufacturing in the U.S. He noted, “Our investment will help WPT accelerate its next phase of growth amid strong market demand for dependable, high-quality capacity.”

Positioning for Future Demand

This investment positions Wilmington PharmaTech to meet the rising domestic and international demand for advanced API development. As the biopharmaceutical sector continues to grow, WPT is set to enhance its role as a crucial manufacturing partner for biopharma innovators.

The collaboration between Wilmington PharmaTech and Curewell Capital signifies a strategic move to capitalize on the evolving landscape of the pharmaceutical manufacturing industry, particularly in the U.S. market. The deal represents a commitment to quality and innovation, which are essential as the sector navigates increasing pressures for reliable and efficient production capabilities.

As Wilmington PharmaTech prepares for its next phase of expansion, the company aims to leverage this investment to strengthen its operational excellence and scientific capabilities, ultimately benefiting its partners and clients in the biopharmaceutical arena.